Premium
Clinical characteristics and analysis of treatment result in children with Ph‐positive acute lymphoblastic leukaemia in Poland between 2005 and 2017
Author(s) -
Zawitkowska Joanna,
Lejman Monika,
ZauchaPrażmo Agnieszka,
Drabko Katarzyna,
Płonowski Marcin,
Bulsa Joanna,
Romiszewski Michał,
MiziaMalarz Agnieszka,
Kołtan Andrzej,
Derwich Katarzyna,
Karolczyk Grażyna,
Ociepa Tomasz,
Ćwiklińska Magdalena,
Trelińska Joanna,
OwocLempach Joanna,
Niedźwiecki Maciej,
Kiermasz Aleksandra,
Kowalczyk Jerzy
Publication year - 2018
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.13142
Subject(s) - imatinib , medicine , chemotherapy , lymphoblastic leukemia , gastroenterology , imatinib mesylate , pediatrics , leukemia , myeloid leukemia
Objective The aim of this study was to analyse the clinical characteristics and outcome of children diagnosed with Ph+ ALL . Material and Methods A total of 2591 newly diagnosed ALL children were treated in Poland between the years 2005 and 2017. Of those, 44 were diagnosed with Ph(+) ALL . The patients were treated according to protocols: ALL IC ‐ BFM 2002 and 2009 (26 patients), EsPh ALL (12 patients), initially ALL IC ‐ BFM and then EsPh ALL (6 patients). Results The median of follow‐up in the observed group was 3 years. Overall survival ( OS ) and event‐free survival ( EFS ) of Ph+ ALL group were 0.73 and 0.64. OS and EFS of patients after HSCT were 0.78 and 0.66, while without HSCT were 0.6 and 0.6, P = 0.27 and 0.63. OS was 0.8 for patients treated with chemotherapy plus imatinib and 0.61 for chemotherapy alone, P = 0.22, while EFS was 0.66 (imatinib therapy) and 0. 61 (without imatinib), P = 0.41. Conclusion Our study suggests that adding imatinib to intensive chemotherapy seems to improve outcome. However, this study was limited by a small number of patients and a variety of chemotherapy regimens with or without imatinib.